Descripción del proyecto
Un análisis más detallado de los tratamientos oculares y las intervenciones quirúrgicas avanzadas
Las deficiencias visuales son una de las principales causas de discapacidad. En Europa, de media, una de cada treinta personas sufre pérdida de visión. En la actualidad, el tratamiento de enfermedades oculares constituye una prioridad. Sin embargo, el arsenal de medicamentos sigue estando bastante restringido a los fármacos tradicionales a pesar de las mejoras en los tratamientos farmacológicos. En este contexto, el equipo del proyecto financiado con fondos europeos DYE-LIGHT analizará nuevas formas de administrar productos bioterapéuticos y realizar intervenciones quirúrgicas oculares. Más allá de los métodos actuales, que incluyen colirios e inyecciones, el equipo estudiará el uso de láseres pulsados a niveles de energía mucho más bajos que los utilizados actualmente en cirugía ocular en combinación con tintes vitales nanoencapsulados utilizados por los cirujanos para teñir los tejidos.
Objetivo
Ocular diseases affect the quality of life of millions of patients. Despite improvements in pharmacological treatments, the arsenal of medications to treat severe ocular diseases today remains rather restricted to traditional drugs. Use of most modern biotherapeutics like proteins and nucleic acids, could be a major step forward. However, current ways of administration such as eye drops and intravitreal injections, are no longer sufficient to deliver these drugs to most targets in the eye. Therefore, novel concepts allowing biotherapeutics to safely overcome ocular barriers are of high interest. In ocular surgery, pulsed-lasers (P-Ls) are used for ‘tissue cutting’, though safety concerns remain. DYE-LIGHT hypothesizes that strategies which would allow the use of P-Ls in the eye at much lower energy than today, could considerably improve safety and pave the way for both novel ocular therapies and advanced surgical interventions. DYE-LIGHT will explore vital dyes, as used by ocular surgeons to stain tissues, as photosensitizers. DYE-LIGHT follows the recent observation that P-L irradiation of ocular dyes can result in the formation of water vapor nanobubbles (‘dye-based nanobubbles’) and thermophoretic transport (‘dye-based thermophoresis’). Interestingly, these biophysical phenomena occur at a laser energy that is ~ 1000 times less than a P-L alone. As compared to free dyes, dyes encapsulated in nanocarriers are expected to penetrate less into the retina, which might improve safety. Therefore, focus in DYE-LIGHT will be on nano-encapsulated ocular dyes. DYE-LIGHT will explore the potential of dye-based nanobubbles for delivery of nucleic acids in the corneal endothelium and for spatial selective vitreolysis in the eye. Finally, DYE-LIGHT will explore dye-based thermophoresis for controlled transport of nanomedicines injected in the vitreous towards the retina. If successful, this might open new perspectives to improve the efficacy of retinal drug and gene delivery.
Ámbito científico
- natural sciencesbiological sciencesbiochemistrybiomoleculesnucleic acids
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologynanomedicine
- medical and health sciencesclinical medicineophthalmology
- medical and health sciencesclinical medicinesurgerysurgical procedures
Palabras clave
Programa(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régimen de financiación
HORIZON-ERC - HORIZON ERC GrantsInstitución de acogida
9000 Gent
Bélgica